{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:39:55Z","timestamp":1792291195434,"version":"4.4.0"},"reference-count":38,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To explore whether insulin resistance, assessed by estimated glucose disposal rate (eGDR), is associated with cardiorenal risk and whether it modifies finerenone efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>In FIDELITY (N = 13,026), patients with type 2 diabetes, either 1) urine albumin-to-creatinine ratio (UACR) of \u226530 to &amp;lt;300 mg\/g and estimated glomerular filtration rate (eGFR) of \u226525 to \u226490 mL\/min\/1.73 m2 or 2) UACR of \u2265300 to \u22645,000 mg\/g and eGFR of \u226525 mL\/min\/1.73 m2, who also received optimized renin-angiotensin system blockade, were randomized to finerenone or placebo. Outcomes included cardiovascular (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney (kidney failure, sustained decrease of \u226557% in eGFR from baseline, or renal death) composites. eGDR was calculated using waist circumference, hypertension status, and glycated hemoglobin for 12,964 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Median eGDR was 4.1 mg\/kg\/min. eGDR &amp;lt;median (insulin resistant) was associated with higher cardiovascular event incidence regardless of treatment versus \u2265median (insulin sensitive) (incidence rate\/100 patient-years of 5.18 and 6.34 [for finerenone and placebo] vs. 3.47 and 3.76 [for finerenone and placebo], respectively). However, eGDR was not associated with kidney outcomes. There was no significant heterogeneity for effects of finerenone by eGDR on cardiovascular (&amp;lt;median: hazard ratio [HR] 0.81, 95% CI 0.72\u20130.92; \u2265median: HR = 0.92, 95% CI 0.79\u20131.06; P interaction = 0.23) or kidney outcomes (&amp;lt;median: HR = 0.84, 95% CI 0.68\u20131.02; \u2265median: HR = 0.70, 95% CI 0.58\u20130.85; P interaction = 0.28). Overall, finerenone demonstrated similar safety between subgroups. Sensitivity analyses were consistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Insulin resistance was associated with increased cardiovascular (but not kidney) risk and did not modify finerenone efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-1420","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T22:05:02Z","timestamp":1703714702000},"page":"362-370","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":43,"title":["Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance"],"prefix":"10.2337","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1683-9276","authenticated-orcid":false,"given":"Thomas","family":"Ebert","sequence":"first","affiliation":[{"name":"1Medical Department III \u2013 Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"2Department of Cardiology of German Heart Center Charit\u00e9; Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[{"name":"3Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain"},{"name":"4CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"5Faculty of Sport Sciences, European University of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[{"name":"6Department of Medicine, University of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-7151","authenticated-orcid":false,"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[{"name":"7Tulane University Health Sciences Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"8Division of Endocrinology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[{"name":"9Department of Diabetology, Endocrinology and Nephrology, University Clinic, T\u00fcbingen, Germany"},{"name":"10Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, University of T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"11German Center for Diabetes Research, Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawatscheck","sequence":"additional","affiliation":[{"name":"12Clinical Research, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[{"name":"13Data Science and Analytics, Bayer PLC, Reading, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[{"name":"14Medical Affairs, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"15Steno Diabetes Center Copenhagen, Herlev, Denmark"},{"name":"16Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FIDELIO-DKD and FIGARO-DKD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"2024022320220976300_B1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12882-019-1220-6","article-title":"Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study","volume":"20","author":"Schrauben","year":"2019","journal-title":"BMC Nephrol"},{"key":"2024022320220976300_B2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000479801","article-title":"Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity?","volume":"8","author":"Whaley-Connell","year":"2017","journal-title":"Cardiorenal Med"},{"key":"2024022320220976300_B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4093\/dmj.2021.0280","article-title":"Insulin resistance: from mechanisms to therapeutic strategies","volume":"46","author":"Lee","year":"2022","journal-title":"Diabetes Metab J"},{"key":"2024022320220976300_B4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fendo.2018.00693","article-title":"The evolving importance of insulin signaling in podocyte health and disease","volume":"9","author":"Lay","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024022320220976300_B5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2288-11-158","article-title":"Selection of the appropriate method for the assessment of insulin resistance","volume":"11","author":"Borai","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"2024022320220976300_B6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/dom.13110","article-title":"Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes","volume":"20","author":"Nystr\u00f6m","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2024022320220976300_B7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","article-title":"Can clinical factors estimate insulin resistance in type 1 diabetes?","volume":"49","author":"Williams","year":"2000","journal-title":"Diabetes"},{"key":"2024022320220976300_B8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-023-01925-1","article-title":"Insulin resistance estimated by estimated glucose disposal rate predicts outcomes in acute ischemic stroke patients","volume":"22","author":"Lu","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024022320220976300_B9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12916-021-01936-3","article-title":"Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study","volume":"19","author":"Penno","year":"2021","journal-title":"BMC Med"},{"key":"2024022320220976300_B10","first-page":"375","article-title":"Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?","volume":"20","author":"de Jong","year":"2007","journal-title":"J Nephrol"},{"key":"2024022320220976300_B11","doi-asserted-by":"crossref","first-page":"bvad069","DOI":"10.1210\/jendso\/bvad069","article-title":"Estimated glucose disposal rate predicts renal progression in type 2 diabetes mellitus: a retrospective cohort study","volume":"7","author":"Peng","year":"2023","journal-title":"J Endocr Soc"},{"key":"2024022320220976300_B12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12933-021-01394-4","article-title":"Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study","volume":"20","author":"Zabala","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024022320220976300_B13","doi-asserted-by":"crossref","first-page":"R276","DOI":"10.1152\/ajpregu.00280.2020","article-title":"Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease","volume":"320","author":"Jia","year":"2021","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2024022320220976300_B14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","article-title":"Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists","volume":"45","author":"Marzolla","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"2024022320220976300_B15","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc07-0525","article-title":"Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients","volume":"30","author":"Colussi","year":"2007","journal-title":"Diabetes Care"},{"key":"2024022320220976300_B16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ejhf.2740","article-title":"The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure","volume":"25","author":"Lin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2024022320220976300_B17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijchv.2014.03.005","article-title":"Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives","volume":"3","author":"Vizzardi","year":"2014","journal-title":"Int J Cardiol Heart Vessels"},{"key":"2024022320220976300_B18","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","article-title":"Aldosterone production and insulin resistance in healthy adults","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024022320220976300_B19","doi-asserted-by":"crossref","first-page":"819327","DOI":"10.3389\/fphar.2022.819327","article-title":"Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024022320220976300_B20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: a comprehensive review of finerenone","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2024022320220976300_B21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2024022320220976300_B22","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024022320220976300_B23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2024022320220976300_B24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"2024022320220976300_B25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2024022320220976300_B26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/ki.2014.1","article-title":"Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function","volume":"86","author":"Jia","year":"2014","journal-title":"Kidney Int"},{"key":"2024022320220976300_B27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12877-022-03689-x","article-title":"Estimated glucose disposal rate and risk of cardiovascular disease: evidence from the China Health and Retirement Longitudinal Study","volume":"22","author":"Ren","year":"2022","journal-title":"BMC Geriatr"},{"key":"2024022320220976300_B28","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2337\/dc12-1693","article-title":"Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes","volume":"36","author":"Epstein","year":"2013","journal-title":"Diabetes Care"},{"key":"2024022320220976300_B29","doi-asserted-by":"crossref","first-page":"6425359","DOI":"10.1155\/2017\/6425359","article-title":"Insulin resistance and chronic kidney disease in patients with type 1 diabetes mellitus","volume":"2017","author":"Vladu","year":"2017","journal-title":"J Nutr Metab"},{"key":"2024022320220976300_B30","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1111\/dom.15197","article-title":"The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: post hoc analysis of the FIDELITY study","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2024022320220976300_B31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HJR.0b013e32833c1aa3","article-title":"Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE","volume":"18","author":"Czernichow","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2024022320220976300_B32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1017\/S0029665119001034","article-title":"Ethnic distinctions in the pathophysiology of type 2 diabetes: a focus on black African-Caribbean populations","volume":"79","author":"Goff","year":"2020","journal-title":"Proc Nutr Soc"},{"key":"2024022320220976300_B33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11306-022-01905-8","article-title":"Ethnic disparities attributed to the manifestation in and response to type 2 diabetes: insights from metabolomics","volume":"18","author":"Vasishta","year":"2022","journal-title":"Metabolomics"},{"key":"2024022320220976300_B34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrneph.2016.145","article-title":"The impact of insulin resistance on the kidney and vasculature","volume":"12","author":"Artunc","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2024022320220976300_B35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cmet.2010.08.015","article-title":"Insulin signaling to the glomerular podocyte is critical for normal kidney function","volume":"12","author":"Welsh","year":"2010","journal-title":"Cell Metab"},{"key":"2024022320220976300_B36","doi-asserted-by":"crossref","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2024022320220976300_B37","first-page":"661","article-title":"Insulin resistance in chronic kidney disease: its clinical characteristics and prognosis significance","volume":"30","author":"Caravaca","year":"2010","journal-title":"Nefrologia"},{"key":"2024022320220976300_B38","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5414\/CNP71643","article-title":"Insulin resistance is a risk factor for the progression of chronic kidney disease","volume":"71","author":"Kobayashi","year":"2009","journal-title":"Clin Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/3\/362\/748503\/dc231420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/3\/362\/748503\/dc231420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:22:40Z","timestamp":1708701760000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/3\/362\/154043\/Outcomes-With-Finerenone-in-Patients-With-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,27]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1420","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}